ClinicalTrials.gg
Status unknownNCT01761149Updated Jan 4, 2013

Effect of Higher Doses of Remifentanil on Postoperative Pain in Patients Undergoing Thyroidectomy

A Phase 4 interventional study of Remifentanil in Nodular Goiter, sponsored by Central South University. Status unknown at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2013-01-04.

Sponsored by Central South University · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2013), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Extensive clinical studies have shown that intraoperative infusion high dose of remifentanil (0.2ug/kg/min) induced postoperative hyperalgesia. Recent experimental study however suggests that higher dose of remifentanil may attenuate postoperative hyperalgesia. Thus, the present study is designed as a "proof of principle" study and hypothesizes that higher dose of remifentanil may reduce postoperative pain in patients.

Read the detailed description

Remifentanil, an ultra-short acting opioid, is widely used in the patients undergoing surgery. However, extensive studies report that remifentanil,administered at 0.2ug/kg/min or 0.4ug/kg/min intraoperatively, can result in postoperative hyperalgesia and increase the consumption of analgesics when compared with low dose (0.05ug/kg/min). However, a recent experimental study shows that large dose of remifentanil can inhibit pain hypersensitivity through erasing the spinal sensitization of pain. The present study thus hypothesizes that higher dose of remifentanil (1.2ug/kg/min) may attenuate postoperative pain. The present study will compare the effect of two different dose of remifentanil (0.2ug/kg/min and 1.2ug/kg/min) on postoperative pain. Patients undergoing thyroidectomy will be recruited, and mechanical threshold will be measured in the remote region of surgical site preoperatively. The patients will be randomly divided by two groups, 0.2ug/kg/min (group I) and 1.2ug/kg/min (group II). After operation, mechanical threshold and visual analogue scale (VAS) will be measured as the indicators of postoperative pain. The consumption of morphine will also be compared between these two doses of remifentanil.

The present study may find optimized dose of opioid usage in the patients undergoing surgery to relieve the postoperative pain.

02

Conditions studied

  • Nodular Goiter

Keywords

  • remifentanil,
  • opioid,
  • hyperalgesia,
  • visual analogue score
  • thyroidectomy,
03

In context

Goiter, Nodular

19 studies on the registry are indexed under Goiter, Nodular; 6 are open to participants now.

This study's planned enrollment of 60 is below the median of 68 across 11 interventional studies indexed under Goiter, Nodular.

Browse Goiter, Nodular studies →

Lead sponsor

Central South University is the lead sponsor of 134 studies on the registry; 32 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ASA Grade I or II
  • Age 18-60 years old
  • \<35,

Exclusion criteria

Exclusion Criteria:

  • do not consent,
  • Chronic pain,
  • used pain killer,
  • undergoing operation previously
  • diabetes or the other diseases affecting the sensory.
  • difficult intubation;
  • unexpected surgical complication such as bleeding;
  • psychiatric disorders;
  • drug or alchohol abuse
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Remifentanil (Low dose)

    remifentanil(Low):dose of 0.2ug/kg/min. The dose of remifentanil is widely used intraoperatively clinically;

    Drug: Remifentanil

  • Experimental
    Remifentanil (High dose)

    The high dose of remifentanil is 1.2ug/kg/min. The does is sometimes used in clinical practice.

    Drug: Remifentanil

Interventions

  • The present study examine two different dose of remifentanil: low dose (0.2ug/kg/min) and high dose (1.2ug/kg/min)

06

What researchers measure

Primary outcomes

  1. Changes of sensory threshold from baseline to postoperative 24hours

    Quantitative sensory threshold in the remote uninjured site (here, the inner forearm) is commonly used to examine the occurrence of postoperative hyperalgesia. The present study will examine the mechanical threshold in two different doses of remifentanil to determine whether high dose of remifentanil induces hyperalgesia

    Time frame: 24 hour

Secondary outcomes

  1. visual analogue score (VAS)

    VAS is widely used to assess postoperative pain. It will be divided as 10 points. Zero refers to no pain and ten refers to extremely pain. Based on this way, we can know the difference of postoperative pain in these two different groups.

    Time frame: 24 hours

Other outcomes

  1. consumption of morphine postoperatively

    Time frame: 24 hours

07

Study locations

1 of 1 sites recruiting
  • Department of Anesthesiology, The Second Xiangya Hospital
    Changsha, Hunan 410011, China
    Recruiting
08

References and documents

Publications

  • Zhang YL, Ou P, Lu XH, Chen YP, Xu JM, Dai RP. Effect of intraoperative high-dose remifentanil on postoperative pain: a prospective, double blind, randomized clinical trial. PLoS One. 2014 Mar 25;9(3):e91454. doi: 10.1371/journal.pone.0091454. eCollection 2014. PubMed 24667391 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 4, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01761149
Responsible party
Ru-Ping Dai (Associate Professor, MD, PhD, Central South University) — Principal investigator
First posted
Jan 4, 2013
Start date
Dec 2012
Primary completion
Mar 2013 (estimated)
Last update
Jan 4, 2013

Study contacts

Ru-Ping Dai, MD, PhD
Contact
Ruping_dai@yahoo.com.cn
86-731-8529 ext. 5970
Ru-Ping Dai, MD
principal investigator · Central South University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remifentanil

Start the discussion